Joe Jimenez, head of pharmaceuticals at Novartis, has been appointed chief executive of the company, effective 1 February 2010. He is taking over from Daniel Vasella who is stepping aside to concentrate on strategic priorities for the group as a whole as chairman of the Board of Directors. Dr Vasella served as Novartis’s CEO for 14 years and as chairman and CEO for 11 years. David Epstein, head of oncology, will become head of the pharmaceuticals division. In addition, Jon Symonds will take over as chief financial officer from Raymund Breu who is retiring.
Copyright 2010 Evernow Publishing Ltd